Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116048 | 0.89 | P4HTM (0.54) | ORAI1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3116564 | 0.86 | PTPN1 (0.50) | ORAI1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3117708 | 0.86 | KCNQ3 (0.56) | BRAFMAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14609473 | 0.86 | ULK1 (0.47) | ORAI1MAPTBTKALDH1A1KDM4E | |
| SCHEMBL3117351 | 0.83 | BRAF (0.50) | BRAFMAPTKDM4E | |
| SCHEMBL3120279 | 0.82 | RAB9A (0.57) | MAPTRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3109283 | 0.81 | PTPN1 (0.51) | MAPTRAB9ASMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL3117290 | 0.79 | TRPV1 (0.47) | MAPTRAB9ASMN1; SMN2CYP1A2HDAC6 | |
| SCHEMBL3117348 | 0.78 | SMN1; SMN2 (0.58) | MAPTRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3107074 | 0.78 | CYP11B1 (0.46) | MAPTRAB9ACYP1A2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| CN-101291923-A | Pyrazolone derivatives for the treatment of tuberculosis | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1919890-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020426-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | TREH, TYMP, EPX | ORAI1 4667/4885BRAF 1900/4885CSF1R 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.